Lance W. Sealey

Array ( [id] => 14338883 [patent_doc_number] => 20190151414 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-23 [patent_title] => ANTI-COMPLEMENT FACTOR C4/C4B ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/300207 [patent_app_country] => US [patent_app_date] => 2017-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27785 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16300207 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16915914 [patent_doc_number] => 20210189006 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => ANTIBODY-CONTAINING PREPARATION [patent_app_type] => utility [patent_app_number] => 16/093495 [patent_app_country] => US [patent_app_date] => 2017-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8052 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16093495 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17968254 [patent_doc_number] => 11485768 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-01 [patent_title] => Immunogenic CD1d binding peptides [patent_app_type] => utility [patent_app_number] => 16/091549 [patent_app_country] => US [patent_app_date] => 2017-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18045 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16091549 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16236877 [patent_doc_number] => 20200254111 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => ANTIBODY-DRUG CONJUGATE COMPRISING MODIFIED ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/088804 [patent_app_country] => US [patent_app_date] => 2017-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11672 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 133 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16088804 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20173027 [patent_doc_number] => 12391759 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-19 [patent_title] => Methods related to engineered Fc constructs [patent_app_type] => utility [patent_app_number] => 16/081829 [patent_app_country] => US [patent_app_date] => 2017-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 14 [patent_no_of_words] => 26269 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 415 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16081829 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16948419 [patent_doc_number] => 20210207110 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => HUMAN KYNURENINASE ENZYME VARIANTS HAVING IMPROVED PHARMACOLOGICAL PROPERTIES [patent_app_type] => utility [patent_app_number] => 16/081492 [patent_app_country] => US [patent_app_date] => 2017-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16691 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16081492 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13898933 [patent_doc_number] => 20190038671 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-07 [patent_title] => ENGINEERED MAMMALIAN CELLS FOR CANCER THERAPY [patent_app_type] => utility [patent_app_number] => 16/075220 [patent_app_country] => US [patent_app_date] => 2017-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54571 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16075220 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13522115 [patent_doc_number] => 20180312600 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-01 [patent_title] => METHODS AND COMPOSITIONS FOR MODIFYING MACROPHAGE POLARIZATION INTO PRO-INFLAMMATORY CELLS TO TREAT CANCER [patent_app_type] => utility [patent_app_number] => 15/769689 [patent_app_country] => US [patent_app_date] => 2016-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12718 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15769689 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17665329 [patent_doc_number] => 11359010 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-14 [patent_title] => Humanized anti-S100A9 antibody and uses thereof [patent_app_type] => utility [patent_app_number] => 16/316146 [patent_app_country] => US [patent_app_date] => 2016-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 22 [patent_no_of_words] => 7745 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16316146 [rel_patent_id] =>[rel_patent_doc_number] =>)